What Nacrez Treats: Main Uses and Benefits

Nacrez is commonly used to help with fertility management for women of reproductive age. Its use may be part of symptomatic management by supporting a sense of stability concerning family planning.

A key benefit is its application as an estrogen-free option, which is relevant in clinical settings where patients experience symptoms related to systemic imbalance or health factors that recommend avoiding combined estrogen-progestin regimens. This includes women who are breastfeeding/lactating and patient groups with health factors that recommend an estrogen-free regimen. Nacrez may support the management of fertility risks for patients with certain physiological factors.

Beyond its primary function, Nacrez may be part of symptomatic management associated with the menstrual cycle. Through continuous hormonal support, it is commonly used to help ease the overall symptom burden of heavy menstrual bleeding (menorrhagia) and may assist with maintaining functional stability when symptoms are more noticeable. This modification of the menstrual pattern supports improved comfort and functional stability during symptomatic periods.

Quick Fact: Relief for Heavy Menstrual Bleeding and Estrogen Sensitivity

Nacrez, a progestogen-only contraceptive (like desogestrel), has specific eligibility rules established by regulatory authorities.

Populations Who Must NOT Use Nacrez (Contraindications)

Official labeling strictly prohibits the use of Nacrez in individuals with:

• A known or suspected pregnancy.
• An active venous thromboembolic disorder (e.g., Deep Vein Thrombosis or Pulmonary Embolism).
• Current or history of severe hepatic disease until liver function values have returned to normal.
• Known or suspected sex-steroid sensitive malignancies (e.g., breast cancer).
• Undiagnosed vaginal bleeding.
• Hypersensitivity (allergy) to the active substance or its excipients.

Eligibility for Special Populations

• Breastfeeding: Nacrez may be used during lactation, as regulatory data indicates it does not negatively influence the quality or production of breast milk, though infant development should be observed.
• Age Groups: The safety and efficacy are not established in adolescents under 18 years of age due to a lack of available clinical data. Use in older adults is generally permitted.
• Restrictions: Use must be stopped or carefully considered in cases of long-term immobilization due to surgery or illness.

The official regulatory profile for Nacrez, a Desogestrel progestogen-only contraceptive, outlines specific interaction patterns based on the drug’s metabolism.

Enzyme-Mediated Interaction Risks

The primary concern involves pharmacokinetic interactions with drugs that influence the cytochrome P450 CYP3A4 enzyme system. Co-administration with enzyme-inducing medicinal products, such as the anticonvulsants Carbamazepine and Phenytoin, or the antibiotic Rifampicin, results in an increased clearance of the active progestin, etonogestrel. This effect formally leads to diminished contraceptive efficacy. Conversely, co-administration with strong or moderate CYP3A4 inhibitors, including Ketoconazole or Clarithromycin, may slow metabolism, resulting in increased serum concentrations of the progestin.

Herbal Products and Other Medications

The herbal product St. John’s Wort (Hypericum perforatum) is a documented enzyme inducer that may also reduce contraceptive effectiveness due to increased clearance of the hormone. Additionally, the progestin may interfere with the metabolism of other co-administered substances; regulatory documents note that the plasma concentration of drugs like Ciclosporin may be increased.

Interaction-Related Restriction

Official prescribing information imposes a key management rule for interactions with enzyme inducers: the use of a non-hormonal barrier method is required during the period of co-administration and must be continued for 28 days after discontinuation of the enzyme-inducing agent. No population-specific interaction cautions are formally documented.

How Nacrez works: Mechanism of Action

Nacrez functions via its active metabolite, etonogestrel, a potent agonist for progesterone receptors (PR) across the reproductive system. The mechanism operates across three distinct physiological domains. Central action involves binding to PR in the hypothalamus and pituitary gland, which suppresses the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This cascade centrally suppresses the final maturation and release of an egg from the ovary, a process known as anovulation.

Peripheral actions include targeting PR in the cervical glands, where activation alters the volume and increases the viscosity of the cervical fluid, creating a physical barrier that restricts sperm transit into the uterus. Concurrently, the drug acts on PR in the endometrium (uterine lining), causing structural atrophy and modification of the tissue, which results in the tissue's reduced receptivity to a fertilized egg.

Administration Guidelines for Nacrez

Nacrez is a progestogen-only contraceptive formulated as a film-coated tablet for oral administration. The regimen requires continuous, precise daily dosing to maintain effectiveness, differentiating it from combined oral contraceptives that use a hormone-free interval.

---

Instruction	Detail
Route of Administration	Oral route only. Tablets are swallowed whole, typically with water.
Standard Dosing Schedule	One tablet daily containing 75 microgram of Desogestrel. This is the dose for the contraceptive use.
Timing in Relation to Meals	May be taken with or without food.

---

Frequency, Schedule, and Procedural Constraints

Administration must occur once daily at approximately the same time each day, ensuring the interval between two doses is always 24 hours. A new 28-day blister pack is started immediately after the previous one is finished, with no pill-free interval.

• Missed Dose Protocol: If the tablet is taken less than 12 hours late, the missed tablet should be taken immediately and the next tablet taken at the usual time. If the delay is more than 12 hours, an additional non-hormonal barrier method is required for the following 7 days.
• Gastrointestinal Handling: In the event of severe vomiting or diarrhea within 3–4 hours of tablet intake, the episode is treated as a missed tablet, requiring a subsequent action to maintain the regimen.

Connection to the Overall Use Protocol

These instructions establish a continuous, time-critical regimen where precise adherence to the 24-hour interval is essential for proper use. The protocol defines both the standard daily intake and the specific procedural steps necessary to maintain the administration integrity when the routine is disrupted.

Research Evidence / Overview of Studies

Evaluation in Pain and Inflammation

Research evaluated the drug in studies exploring its potential effect on pain and inflammation. Studies assessed how quickly the drug reached peak concentration in the body, and evaluated its potential effect on acute symptoms.

Primary Studies: Osteoarthritis (OA)

The primary evidence includes studies that evaluated the drug in treating osteoarthritis (OA). These studies typically focused on data from the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

• Pain Evaluation: The initial Phase III Randomized Controlled Trials (RCTs) reported data on the WOMAC pain subscale score.
• Physical Function: Trials also assessed data on the physical function subscale, which measures the effect of the drug on a patient's daily activities.
• Combination Treatment: Some research has explored the drug's use alongside physical therapy.

Secondary Studies: Acute Pain Indications

Research has also explored the use of the drug in acute pain, including acute gout and pain following dental surgery.

• Acute Gout Flares: For acute gout flare-ups, research evaluated the drug in relation to older nonsteroidal anti-inflammatory drugs (NSAIDs) over 48 hours.
• Post-Surgical Pain: This treatment option has also been evaluated in studies exploring its use for post-operative pain. Initial reports evaluated the drug in relation to pain scores.

Safety and Tolerability Profile

Clinical trials are essential to understand how a drug is tolerated.

• Long-Term Tolerability: A long-term safety study (1 year) examined the drug's tolerability and reported a side-effect profile.
• Gastrointestinal (GI) Events: Several pooled analyses have evaluated the incidence of serious GI side effects.
• Drug-Drug Interactions: Studies explored the drug's use alongside blood thinners.

Pharmacokinetics and Administration Studies

• Absorption and Metabolism: Pharmacokinetic studies examined the drug's absorption parameters when taken with food.
• Dosing Schedule: Research included evaluations based on different daily timing.

Key Studies & References Efficacy and Safety of Nacrez in Knee Osteoarthritis: A Phase III Randomized Controlled Trial (WOMAC data source)

Common questions about Nacrez (FAQ)

---

Q: Are there any common foods or drinks that should be avoided when taking Nacrez?

Regulatory information indicates caution regarding certain substances, such as grapefruit juice, as it has been shown to potentially slow the metabolism of the active hormone. This general caution relates to possible changes in drug concentrations. The official label confirms the tablet may be taken with or without food.

---

Q: Is Nacrez considered a high-risk medication?

Nacrez is a prescription-only medicine, and official labeling outlines rare but serious risks that necessitate medical oversight. These documented risks include the possibility of venous thromboembolism (VTE) (blood clots) and an association with certain rare malignancies. The status as a prescription-only medicine means its use is typically managed by a healthcare professional, given the documented risks.

---

Q: Are there any specific vitamins or supplements that are known to interact with Nacrez?

Official regulatory documents confirm that the herbal product St. John's Wort can interact with Nacrez. This interaction may increase the rate at which the hormone is cleared from the body, potentially reducing its contraceptive effectiveness. Information regarding any supplements should be reviewed by a healthcare professional.

---

Q: Why do official documents mention 'contraindications' for Nacrez?

Contraindications are a critical part of official drug information required by regulatory agencies. They are defined conditions or situations where the medication must not be used because the potential risks of harm to the patient are clearly greater than any potential benefit. This regulatory measure ensures comprehensive patient safety.

---

Q: What is the significance of the placebo group in the Nacrez clinical trials?

The placebo group is a fundamental element of clinical trials, which are often randomized and controlled. Its role is to help researchers compare outcomes and distinguish the drug's true clinical effect from the effect observed when a non-active substance is used.

---

Q: Why do some patient information leaflets list so many possible side effects for Nacrez?

Regulatory bodies like the FDA and EMA require manufacturers to list all possible side effects reported during clinical trials. This regulatory requirement ensures comprehensive transparency regarding all documented risks, regardless of their frequency.

---

Q: How is Nacrez different from the most common treatment for the same condition?

Official information describes Nacrez as a progestogen-only pill (sometimes called a mini-pill). This means it only contains one type of hormone and does not contain oestrogen. This formulation makes it a suitable contraceptive option for women who require or prefer an oestrogen-free method.

---

Q: How long after starting Nacrez can someone typically expect to see results? / Does Nacrez work right away, or does it take time to build up in the system?

The drug's onset of action depends on when it is started in the menstrual cycle. Official administration instructions note that if the tablet is not started on the first day of the menstrual cycle, the use of an additional, non-hormonal barrier method is typically recommended for the first 7 days to support contraceptive effectiveness.

---

Q: What happens if I stop using Nacrez suddenly? / If I feel better, can I stop taking Nacrez on my own?

Nacrez is a contraceptive that relies on continuous, precise daily dosing to maintain its effectiveness. Stopping the medication suddenly means that the protective effect is lost, and the risk of pregnancy is expected to return promptly. Its function is preventative, not dependent on resolving symptoms.

---

Q: Can Nacrez affect my ability to drive or operate machinery?

According to the official prescribing information, Nacrez has no known effects that would impair a person's ability to drive or safely operate machinery.

---

Q: Is Nacrez approved by the FDA?

Yes, the active ingredient in Nacrez, Desogestrel, has been reviewed and approved by regulatory bodies, including the US Food and Drug Administration (FDA), for use in hormonal contraception.

---

Q: What does the term 'off-label use' mean for a drug like Nacrez?

The term off-label use refers to using a medicine for a purpose, condition, or dosage that is not officially approved and detailed in the government-reviewed regulatory label. Use of the drug outside of its official indications is not supported by the product's label.

---

Q: Can Nacrez affect blood sugar levels?

Regulatory documents note that the active ingredient in Nacrez may cause minor changes in carbohydrate (blood sugar) metabolism. This effect is typically reviewed in patients with conditions like diabetes by a healthcare professional.

---

Q: Is there a generic version of Nacrez available?

The active ingredient found in Nacrez, Desogestrel, is widely available as generic products. These generic versions have been reviewed and approved by regulatory agencies like the FDA as being therapeutically comparable to the original formulation.

---

Q: Are there specific official warnings about using alcohol with Nacrez?

Regulatory warnings advise caution regarding the use of alcohol with hormonal contraceptives. Alcohol may potentially increase the central nervous system effects of ethanol itself when used with this type of medication.

---

Q: Can Nacrez interact with treatments for high blood pressure?

While specific blood pressure treatments are not always listed as interactions, the drug's official label advises caution because hormonal contraceptives may affect blood pressure levels. The drug's label indicates that blood pressure is typically monitored in patients with pre-existing hypertension or cardiovascular risk factors.

---

Q: Is Nacrez a scheduled or controlled substance?

No, Nacrez is legally classified as a prescription-only medicine. It is not classified as a scheduled or controlled substance under the regulatory schedules, which are reserved for medications with a high potential for dependence or abuse.

---

Q: Does Nacrez require any special monitoring or testing while using it?

Official guidance indicates that blood pressure and any cardiovascular risk factors are typically regularly monitored during the use of hormonal contraceptives. This monitoring is part of standard care to manage risks documented in the regulatory profile.

---

Q: Is Nacrez only for long-term use?

Yes, Nacrez is indicated for the prevention of pregnancy and is intended for continuous long-term use. To maintain contraceptive efficacy, the medication requires daily intake without a break.

---

Q: Does taking Nacrez make people sensitive to sunlight?

Official labeling advises caution for individuals with a history of chloasma (skin darkening or pigmentation). Women with this condition are advised to avoid exposure to sunlight and UV radiation while taking Nacrez.

How to Store and Dispose of Nacrez

Official regulatory documents define specific storage and disposal requirements for Nacrez (desogestrel) to ensure product stability and safety.

Storage Requirements

Storage Condition	Requirement
Temperature	Store below 30 C (2 C to 30 C range).
Protection	Must be stored to protect from light and moisture.
Packaging	Keep the blister pack in the original aluminum laminated sachet.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The full shelf-life is 3 years when stored in the unopened sachet. Once the sachet is first opened, the medicine must be used within 1 month.

Disposal instructions state that unused or expired Nacrez must be handled in accordance with local requirements. The medicine must not be thrown away via wastewater or household waste to prevent environmental contamination.